Natterman Noscasan (Noscapine Hydrochloride Monohydrate)

Noscapine Hydrochloride Monohydrate, the active ingredient in Natterman Noscasan, is an antitussive (alkaloid) presented as an oral dosage form for oral use. It is employed to suppress cough in adults and children when a non‑opioid option is preferred.

GNH USA supplies Natterman Noscasan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides batch‑tested product for global distribution.

Natterman Noscasan, a centrally acting antitussive, is used to manage cough associated with various respiratory conditions.

Acute cough: provides symptomatic relief of cough caused by common colds or upper respiratory infections. Chronic non‑productive cough: helps reduce persistent dry cough when other treatments are ineffective. Cough due to bronchitis: suppresses irritating cough reflex in acute bronchitis.

Adverse reactions to Natterman Noscasan are generally mild, but some patients may experience more serious events.

Common Side Effects: - Nausea: mild stomach upset. - Dizziness: transient light‑headedness. - Drowsiness: increased sleepiness. - Headache: mild to moderate.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling of face or throat. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Neutropenia: reduced white blood cell count, increasing infection risk.

When prescribing Natterman Noscasan, clinicians should consider several safety aspects.

Pregnancy: safety not established; avoid unless clearly needed. Breastfeeding: caution as drug may be excreted in milk. Renal impairment: monitor and adjust if necessary. Concomitant CNS depressants: may enhance sedation. Known hypersensitivity: contraindicated in patients with allergy to noscapine. Store at ambient temperature: keep in original container, protect from moisture and light.

Natterman Noscasan may interact with other medicines; awareness of potential interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - CNS depressants: additive sedation and respiratory depression. - MAO inhibitors: risk of enhanced central effects. - Antihistamines: increased drowsiness.

Moderate Interactions (Monitor Closely): - CYP450 substrates: noscapine may alter metabolism of certain antibiotics. - Antacids: may affect oral absorption. - Alcohol: can potentiate sedative effects.